Patients must not have clinically significant cardiovascular disease (New York Heart Association class III or IV heart failure), uncontrolled clinically significant atrial or ventricular cardiac arrhythmias, or any of the following within the past  months: myocardial infarction, new evidence of transmural infarction on electrocardiogram (ECG), unstable angina, coronary angioplasty
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on ECG
Evidence of New York Heart Association (NYHA) class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past  months
New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past  months, or unstable arrhythmia.
New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial infarction, within the past  months, unstable arrhythmia, or known pericardial disease.
New York Heart Association classification III or IV cardiovascular disease or recent myocardial infarction or unstable angina pectoris or cardiac arrhythmia (<  days)
Have a history of New York Heart Association (NYHA) Class ?, unstable angina, or myocardial infarction (MI) in  months prior to study drug administration
Significant cardiovascular disease with New York Heart Association (NYHA) class II, III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia
Significant cardiovascular disease, such as New York Heart Association cardiac disease (class III or greater), myocardial infarction within  months prior to randomization, unstable arrhythmias, or unstable angina
Cardiac risk factors including:\r\n* Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within  months of signing consent\r\n* Patients with a New York Heart Association classification of III or IV
Symptomatic congestive heart failure (New York Heart Association classification III or IV cardiovascular disease, myocardial infarction =<  months prior to registration, unstable angina pectoris or cardiac arrhythmia =<  months prior to registration, or cardiac arrhythmia
History of pericarditis or pericardial effusion that had required medical or surgical intervention in the last  months, or myocardial infarction or arterial thromboembolic events within  months, or experiencing severe or unstable angina, or New York Heart Association (NYHA) class III or IV disease, or a corrected QC (QTc) interval > . seconds
Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction within  months prior to enrolment, unstable arrhythmia, or evidence of ischemia on ECG.
New York Heart Association classification III or IV cardiovascular disease or recent myocardial infarction or unstable angina pectoris or cardiac arrhythmia =<  days prior to registration
Unstable cardiac disease as defined by one of the following:\r\n* Cardiac events such as myocardial infarction (MI) within the past  months\r\n* NYHA (New York Heart Association) heart failure class III-IV\r\n* Uncontrolled atrial fibrillation or hypertension
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on ECG
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination
New York Heart Association class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG)
Serious cardiac condition within the last  months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV
Patients must not have any grade III/IV cardiac disease as defined by the New York Heart Association (NYHA) criteria unstable angina pectoris, or myocardial infarction within  months of registration; patients with a history of myocardial infarction or irregular heart rate within  months prior to registration should be evaluated by a cardiologist prior to registration
Patients with any of the following:\r\n* History of myocardial infarction within six months\r\n* Unstable angina\r\n* Resting electrocardiogram (ECG) with clinically significant abnormal findings\r\n* New York Heart Association (NYHA) classification of III or IV
Evidence or history of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association class III or IV cardiac disease, severe arrhythmia, myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within months prior to Day , unstable arrhythmia or symptomatic peripheral arterial vascular disease
Serious cardiac condition within the last  months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV
Unstable cardiac disease as defined by one of the following:\r\n* Cardiac events such as myocardial infarction (MI) within the past  months\r\n* NYHA (New York Heart Association) heart failure class III-IV\r\n* Uncontrolled atrial fibrillation or hypertension
Has a history of cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within  months of signing consent; subjects with a New York Heart Association classification of III or IV
New York Heart Association class III or IV cardiac disease or myocardial infarction within the past  months
Significant cardiovascular disease with NYHA Class III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia.
Patients with any of the following:\r\n* History of myocardial infarction within six months\r\n* Unstable angina\r\n* Resting electrocardiogram (ECG) with clinically significant abnormal findings\r\n* New York Heart Association functional classification of III or IV
Significant cardiovascular disease, including:\r\n* Cardiac failure New York Heart Association (NYHA) class III or IV\r\n* Myocardial infarction, severe or unstable angina within  months prior to study day \r\n* History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular fibrillation)\r\n* Cardiac arrhythmias requiring anti-arrhythmic medications
New York Heart Association Class III or IV (Appendix D) cardiac disease or myocardial infarction within the past  months before screening, or preexisting atrial fibrillation.
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on ECG.
Patients with any of the following: History of myocardial infarction within  months prior to starting treatment; Unstable angina; Resting electrocardiogram (ECG) with clinically significant abnormal findings; New York Heart Association functional classification of III or IV
Serious medical comorbidities such as New York Heart Association class III/IV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past  months
New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past  months, or unstable arrhythmia.
Participants with any of the following:\r\n* History of myocardial infarction within six months\r\n* Unstable angina\r\n* New York Heart Association (NYHA) classification of III or IV
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
Significant cardiovascular disease, including:\r\n* Cardiac failure New York Heart Association (NYHA) class III or IV\r\n* Myocardial infarction, severe or unstable angina within  months prior to study day \r\n* History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular fibrillation)\r\n* Cardiac arrhythmias requiring anti-arrhythmic medications
Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< % or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination. Echocardiogram will be performed during screening evaluation
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia.
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< % or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination; echocardiogram will be performed during screening evaluation
New York(NY) Heart Association Class III or IV cardiac disease or Myocardial infarction within the past  months.
Has significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, ejection fraction (EF) =< % or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within  months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination; echocardiogram will be performed during screening evaluation
Significant cardiovascular disease (New York Heart Association class III or IV cardiac disease), myocardial infarction within the past  months, unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy (use of medication to control heart rate in patients with atrial fibrillation is allowed, if stable medication for at least last month prior to randomization and medication not listed as causing torsade de pointes), or evidence of acute ischemia on electrocardiogram (ECG)
Myocardial infarction within  months prior to CD treatment, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the participant is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
Myocardial infarction within  months prior to CD, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
New York Heart Assoc Class III or IV cardiac disease, myocardial infarction within the past  months before screening, or pre-existing atrial fibrillation.
History of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within  months of enrollment), New York Heart Association Classification III or IV.
Have a history of New York Heart Association (NYHA) Class ?, QTc interval >  milliseconds (ms) on screening electrocardiogram (ECG) per Friderica's formula, unstable angina, or myocardial infarction (MI) in  months prior to study drug administration.
Any of the following comorbid conditions:\r\n* New York Heart Association classification III or IV cardiovascular disease\r\n* Recent myocardial infarction (=<  days)\r\n* Uncontrolled infection
New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past  months, unstable arrhythmia
Cardiac risk factors including: \r\n* Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within  months of signing consent\r\n* Patients with a New York Heart Association classification of III or IV
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on ECG.
Myocardial infarction within  months of anti-MIF antibody administration, congestive heart failure (New York Heart Association Class III or Class IV), unstable angina, unstable cardiac arrhythmia requiring medication, or risk factors for polymorphic ventricular tachycardia
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past  months, unstable arrhythmia, or evidence of ischemia on ECG
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last  months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
Have a history of New York Heart Association class ?, unstable angina, myocardial infarction  months prior to study drug
Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last  months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, NYHA (New York Heart Association) Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias
Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer\r\n* This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past  months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease
Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the agent; this includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past  months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association classification III or IV heart disease
Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer; this includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past  months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease
Documented history of a cerebral vascular, unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within  months prior to their first dose of study drug.
